<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70406">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789541</url>
  </required_header>
  <id_info>
    <org_study_id>3/9A</org_study_id>
    <nct_id>NCT01789541</nct_id>
  </id_info>
  <brief_title>Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery?</brief_title>
  <acronym>TABLAS</acronym>
  <official_title>Observational Prospective Case-control Study on Prevalence and Impact of Subclinical Hyperthyroidism in Patients Undergoing Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overt hyperthyroidism (so-called &quot;goiter&quot; in lay language) is a hormonal disturbance that is
      known to increase the risk of atrial fibrillation (a common heart arrhythmia with
      potentially severe consequences) in some patients. Previous research has indicated that even
      slight elevations in thyroid hormone levels - so called subclinical hyperthyroidism - may
      increase this risk. When atrial fibrillation and overt hyperthyroidism are found
      simultaneously in a patient, the hormonal imbalance must be treated first in order to later
      resolve the arrhythmia. It is unclear whether this strategy holds true for subclinical
      hyperthyroidism. Our two hypotheses are: 1) Subclinical hyperthyroidism is more prevalent in
      patients admitted for atrial fibrillation ablation than in the population as a whole, and 2)
      Patients with subclinical hyperthyroidism and atrial fibrillation benefit less from ablation
      than others.

      As a control group, we have chosen patients admitted for ablation of AV-nodal Reentry
      Tachycardia at the same clinics as the cases. No correlation has ever been shown between
      AV-nodal Reentry Tachycardia and hyperthyroidism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prevalence of subclinical hyperthyroidism in patients undergoing atrial fibrillation ablation</measure>
    <time_frame>1 day (Measured upon inclusion)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent atrial fibrillation after ablation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">458</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Subclinical Hyperthyroidism</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <description>Patients with atrial fibrillation undergoing ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-nodal reentry tachycardia</arm_group_label>
    <description>Patients with AV-Nodal Reentry Tachycardia undergoing ablation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atrial fibrillation (cases) or AV-nodal reentry tachycardia (controls)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atrial fibrillation or AV-nodal reentry tachycardia

          -  Fulfills criteria for ablation (severe arrhythmia symptoms; for atrial fibrillation
             patients, having tried at least one antiarrhythmic agent with poor effect)

          -  Admitted for ablation for the first time

          -  Has left blood samples for thyroid status (TSH, free T4, free T3)

        Exclusion Criteria:

          -  Atrial flutter

          -  Overt hyperthyroidism
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mårten Rosenqvist, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet, Institutionen för kliniska vetenskaper vid Danderyds sjukhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Giesecke, M.D.</last_name>
    <phone>+46 70 768 43 88</phone>
    <email>peter.giesecke@ds.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stockholm Arrhythmia Center</name>
      <address>
        <city>Stockholm</city>
        <zip>11861</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fariborz Tabrizi, M.D.</last_name>
      <phone>+46 8 616 52 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hjärtkliniken, Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14147</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Jensen-Urstad, M.D.</last_name>
      <phone>+46 8 5858 00 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Peter Giesecke, M.D</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
